BHV-1300 for Graves' Disease

This trial tests a new treatment called BHV-1300 for individuals with Graves' disease, a condition characterized by an overactive thyroid. The goal is to determine if BHV-1300 can safely and effectively manage hyperthyroidism symptoms (excess thyroid hormone). Participants will receive either the experimental treatment or a placebo (a non-active lookalike). It suits adults with Graves' disease and active hyperthyroidism who have not undergone thyroid surgery or radioactive iodine treatment. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to the potential availability of a new treatment.

The trial requires that you have not taken levothyroxine, desiccated thyroid extract, or T3 within six weeks before starting the study. If you are on these medications, you will need to stop them at least six weeks before the trial begins.

Research has shown that BHV-1300 is safe and well-tolerated by patients. In earlier studies, BHV-1300 did not cause any serious side effects. Patients received it through a simple injection under the skin, and most did not experience troubling reactions or discomfort. The treatment has shown promise in reducing harmful antibodies linked to Graves' disease without causing major issues. So far, the evidence supports that BHV-1300 is safe for people with this condition.¹²³⁴⁵

Unlike the standard treatments for Graves' Disease, which often include antithyroid medications, radioactive iodine, or surgery, BHV-1300 is unique because it is delivered subcutaneously via an autoinjector. This delivery method can potentially offer a more convenient and less invasive option compared to surgery or radioactive treatments. Researchers are excited about BHV-1300 because it targets the condition in a novel way, which could lead to improved outcomes and reduced side effects compared to existing options.

Research has shown that BHV-1300, which participants in this trial may receive, may help treat Graves' disease. In earlier studies, patients who took BHV-1300 experienced more than an 80% drop in harmful antibodies related to Graves' disease. These antibodies, called TSHR autoantibodies, often cause the thyroid to be too active. The treatment quickly reduced these antibodies, and this effect lasted for 12 weeks. This suggests that BHV-1300 could greatly lessen the symptoms of an overactive thyroid in people with Graves' disease.¹²⁴⁵⁶